Complete Metabolic Response in Adenocarcinoma Lung With Lymphangitic Carcinomatosis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 36252925.
- Also identified by DOI 10.1097/RLU.0000000000004463.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pulmonary lymphangitic carcinomatosis refers to the tumor spread into the lymphatic system of the lungs and is considered a poor prognostic marker. We present an interesting case of adenocarcinoma of right lung evaluated with 18 F-FDG PET/CT for baseline staging, with extensive bilateral lung involvement and lymphangitic carcinomatosis pattern. Subsequently, the patient received 3 cycles of carboplatin- and pemetrexed-based chemotherapy regimen along with oral ceritinib. Complete metabolic response and significant reduction in size of the primary lung lesion was noted on response evaluation with 18 F-FDG PET/CT, which is a rare phenomenon.
Medical subject headings
- Adenocarcinoma
- Adenocarcinoma of Lung
- Carcinoma
- Lung Neoplasms